Latest Als (ASX:ALQ) News

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

Small-cap tech buyers chased AI, defence and digital infrastructure this week, while a few names gave back gains after reopening jumps. The biggest moves came from contract wins, fresh capital and clear signs that products are getting closer to real sales.

ALS Limited has detected a malicious cyber attack that temporarily disrupted parts of its operations. The company is actively investigating the incident and working with authorities while restoring affected systems.

ALS Limited confirms a fully franked ordinary dividend of 19.4 cents per share and announces the Dividend Reinvestment Plan price at $21.97 with no discount applied.

ALS Limited has announced a partially franked interim dividend of 19.4 cents per share, payable mid-December, alongside a dividend reinvestment plan priced at $21.97 per share with no discount.

ALS Limited has reported a robust first half for FY26, with revenue climbing 13.3% to $1.7 billion and underlying NPAT rising 17.2%, driven by strong organic growth across all business streams and strategic investments in digital innovation.

ALS Limited has posted a robust first half for FY26 with underlying EBIT growth of 14.7%, driven by strong performance in its Commodities segment and improved Life Sciences results. The company also raised its interim dividend and updated its growth outlook for the year.

ALS Limited has announced an ordinary dividend of AUD 0.194 per share for the half-year ending September 2025, accompanied by a fully franked 30% component and a Dividend Reinvestment Plan with no discount.

ALS Limited reported a robust half-year performance with underlying revenue up 13.3% and net profit after tax rising 17.2%, driven by strong growth in both Commodities and Life Sciences divisions. The company also declared a higher interim dividend and advanced its global expansion strategy.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

ALS Limited reported a robust FY25 with 16% revenue growth to AUD 3 billion, underpinned by strong organic expansion and key acquisitions. Despite slight NPAT decline, the company advances its sustainability agenda and invests in global lab upgrades.

ALS Limited has launched a Share Purchase Plan allowing eligible shareholders to invest up to A$30,000 in new shares at a discounted price, following a recent $350 million institutional placement.